A collection of swine, fish, and cetacean Erysipelothrix rhusiopathiae strains representing 16 serotypes was analyzed for possession of the three currently recognized surface protective antigen (spa)-types: spaA, spaB, and spaC. Polymerase chain reaction (PCR) assays and Western blotting with a SpaA-specific monoclonal antibody demonstrated that spa-type is not confined to specific serotype groups. In particular, the spa-type of strains of aquatic origin was more variable than those of terrestrial origin, and possessed the distinct ability to express more than one spa. In a cross-protection study, mice immunized with an E. rhusiopathiae serotype 2 SpaA-type strain and challenged with various E. rhusiopathiae isolates were completely protected against strains exhibiting a single homologous spa, but variably protected against strains possessing a heterologous spa or those harboring more than one spa-type.
Introduction
Erysipelothrix rhusiopathiae is a bacterial organism which causes erysipelas in a variety of mammals and birds, as well as erysipeloid in humans [1] . Erysipelas is commonly associated with swine, and is characterized by urticarial diamond-shaped lesions which can quickly progress to an acute septicemic infection or death. Chronic erysipelas usually follows an acute infection where self-sustaining, destructive pathological changes in the heart valves and joints produce endocarditis and arthritis, respectively [1] . The disease has recently reemerged in the Midwestern United States [2] but also has an economic and epidemiological impact on animal production and handling worldwide. While outbreaks of the disease are reported most often in swine and turkeys, cetaceans are also commonly affected.
The genus Erysipelothrix contains two accepted species, E. rhusiopathiae which include serotypes 1a, 1b, 2, 4, 5, 6, 8, 9, 11, 12, 15, 16, 17, 19, 21 and N; E. tonsillarum containing serotypes 3, 7, 10, 14, 20, 22 and 23 [3, 4] . Two unclassified Erysipelothrix groups representing serotypes 13 and 18 are also recognized [4] . E. rhusiopathiae is considered to be the pathogenic specie of the genus [5] , and killed and attenuated live vaccines are used to prevent disease. Bacterins for the prevention of swine erysipelas are composed of serotype 2 strains [1] which provide effective cross-protection against serotypes 1a, 1b, and 2 [6, 7] , the most relevant serotypes of swine and turkey erysipelas [1, 8] . These bacterin formulations also protect against other E. rhusiopathiae serotypes, but often to a lesser degree [6, 7, 9] . Marine aquaria also rely on swine strain bacterins to protect against cetacean erysipelas [10, 11] ; however, complete protection is not always attained [11] .
The 64-66 kilodalton (kDa) cell surface protein of E. rhusiopathiae is responsible for eliciting highly protective antibodies [12] [13] [14] , and is considered to be the major immunogenic antigen of the specie [15] . The gene encoding the protective 64-66 kDa protein was first sequenced by Makino et al. [16] who named it, surface protective antigen A (spaA). Recently, two additional types of spa-related genes were detected within E. rhusiopathiae and an unclassified serotype 18 of the genus Erysipelothrix [17] . Amino acid sequence analysis determined that serotypes 1a, 1b, 2, 5, 8, 9, 12, 15, 16, 17 and N possess spaA; serotypes 4, 6, 11, 19 and 21 possess spaB; and the unclassified serotype 18 possesses spaC [17] .
The three molecular groups are distinguished by amino acid sequence and are considered antigenically distinct [17] . In active immunization experiments in mice, recombinant Spa antigens were completely protective against virulent E. rhusiopathiae strains possessing homologous spa [17, 18] , but variably protective against strains possessing heterologous spa-types [17] .
In this study, we evaluated a variety of swine, fish, and cetacean E. rhusiopathiae strains representing all 16 serotypes, and found that spa-type is not confined to specific serotype groups. We then analyzed the ability of a bacterin, formulated with an E. rhusiopathiae serotype 2 strain expressing spaA, to protect mice against a variety of cetacean and fish isolates of known Spa-type.
Materials and methods
2.1. Bacterial strains, growth conditions, and challenge preparation E. rhusiopathiae strains used in this study are listed in Table 1 . E. rhusiopathiae strains from R.L. Wood were serotyped at the USDA National Animal Disease Center or National Veterinary Services Laboratories (Ames, IA) and fish and cetacean strains obtained from the John G. Shedd Aquarium (Chicago, IL) were serotyped at the Veterinary Diagnostic Laboratory, Iowa State University College of Veterinary Medicine (Ames, IA).
Cultures were streaked for isolation and grown on 5% bovine blood agar at 37 • C and propagated as previously documented [17] . Strains used for testing in mice were Piquet, Immiayuk, Quitz, Naluark, Kayavak, Large Herring 182, and Large Herring 911. Overnight cultures were adjusted to 74.0%T ± 0.2 in a spectrophotometer set at 600 nm prior to preparing dilutions for injection in mice.
PCR amplification
Genomic DNA of E. rhusiopathiae strains was purified from 1.0 mL of overnight culture using QIAamp ® DNA Mini Kit (Qiagen, Valencia, CA). The following primers were designed from the protective domain of spaA of E. rhusiopathiae strain Fujisawa (GenBank accession AB019124) using Oligo 6 software (Molecular Biology Insights, Inc., Cascade, CO) and custom synthesized (Iowa State University DNA Facility, Iowa State University, Ames, IA): spaA2F, 5 -CCA AAG GGG TAC CAA AGT T-3 , corresponding to position 259-277, and spaA2R, 5 -GAT TCG GGT TTT GAT TGA-3 , corresponding to position 1328-1311. Polymerase chain reaction was performed in a 50 L reaction mixture that contained final concentrations of one unit Platinum ® Taq DNA polymerase (Invitrogen, Carlsbad, CA), 1× reaction buffer, 1.5 mM MgCl 2 , 0.2 mM dNTPs, and 0.2 M each primer. Samples were subjected to initial denaturation at 94 • C for 5 min; 30 cycles of denaturation at 94 • C for 30 s, annealing at 58 • C for 30 s, and extension at 72 • C for 1 min; with a final extension at 72 • C for 7 min.
The following primers were synthesized (Iowa State University DNA Facility) and used in PCR assays according to previously described reports: primer 1, 5 -ATG AAA AAG AAA AAA CAC CTA-3 , and primer 2, 5 -CTA TTT TAA ACT TCC ATC GTT-3 , were used to amplify whole spaA [17] ; primer 3, 5 -ATG AAA AAG AAA AAA CAC CTA TTT CCG AAA GTA-3 , and primer 4, 5 -CTA TTT TAA ACT TCC ATC GTT CTT AAA TGC ATA-3 , were used to amplify whole spaB or spaC [17] ; ERY-1F, 5 -ATC GAT AAA GTG TTA TTG GTG G-3 , and ERY-2R, 5 -CGA GTG TGA ATC CGT CGT CTC-3 , were used to verify the species of Erysipelothrix strains [19] .
Sequencing of the spa protective domain
A 1070 base pair (bp) fragment of the protective domain of spaA from genomic DNA of E1-6P, Immiayuk, Piquet, Large Herring 182, and Large Herring 911 was amplified by PCR with primer set spaA2F/R. The PCR product from each strain was purified using the MinElute ® PCR purification kit (Qiagen) and inserted into the cloning vector pCR ® 4-TOPO ® (Invitrogen) and transfected into OneShot ® TOP10 chemically competent Escherichia coli (Invitrogen) following the manufacturer's instructions. Plasmids were purified using the PureLink TM Quick Plasmid Miniprep kit (Invitrogen). Both strands of DNA of cloned PCR products were sequenced on a Model 3730xl DNA Analyzer (Applied Biosystems, Carlsbad, CA) using a primer-walking procedure starting with vector primers T3 and T7. DNA sequences were assembled using the SeqMan program of the DNASTAR software package (DNASTAR Inc., Madison, WI) and translated into amino acid sequence using EMBOSS Transeq [20] . Amino acid sequences were aligned with Spa sequences of E. rhusiopathiae strains Fujisawa (GenBank accession AB019124), SE-9 (AB024084), Dolphin E-1 (AB238212), and Erysipelothrix strain 715 (AB238210) using the T-Coffee multiple sequence alignment tool [21] .
Antigen and antibody preparation
Surface antigens of E. rhusiopathiae were obtained by extraction with Triton X-100 (Sigma-Aldrich, Inc., St. Louis, MO) as previously described [12, 14] and stored at −80 • C.
The monoclonal antibody ERHU-B60-91 was produced by vaccinating mice with a bacterin composed of E. rhusiopathiae serotype 2 strains SE-9, CN 3461, CN 3342, and AN-4 as previously described [22] . The antibody has been shown to be specific for the protective domain of SpaA (data not shown).
SDS-PAGE and Western blot
Total protein of each E. rhusiopathiae antigen preparation was estimated using the BCA TM Protein Assay (Thermo Scientific, Rockford, IL). Approximately 50 g of protein per sample per well was separated in NuPAGE ® Novex Bis-Tris 4-12% gradient gels (Invitrogen) in MOPS buffer under reducing conditions. Separated proteins were transferred to nitrocellulose membranes and blocked in 20 mM Tris-500 mM NaCl-0.5% Tween 20 (TTBS, pH 7.5). The proteins were probed with the SpaAspecific monoclonal antibody, ERHU-B60-91 [1, 22] , and visualized with goat-anti-mouse IgG-horseradish peroxidase conjugated antibody (Kirkegaard and Perry Laboratories, Gaithersburg, MD) and 3,3 ,5,5 -tetramethylbenzidine (TMB) and TMB Membrane Enhancer (Kirkegaard and Perry Laboratories) substrate solution.
Separated total protein of each sample was visualized by staining duplicate SDS-PAGE gels with SimplyBlue TM SafeStain (Invitrogen) or by staining duplicate nitrocellulose membranes with AuroDye TM Forte (GE Healthcare, Buckinghamshire, UK).
Animals
CF-1 mice (Charles River Laboratories, Wilmington, MA) 8-10 weeks old were used for each experiment. Mice were provided food and water ad libitum. All management and experimental procedures were performed in accordance with the requirements of the USDA Center for Veterinary Biologics-National Veterinary Services Laboratory Animal Care and Use Committee which conform to provisions of the Animal Welfare Act (Public Laws 85-544 and subsequent amendments).
Erysipelothrix rhusiopathiae strain lethality testing
The mouse 50% lethal dose (LD 50 ) of each E. rhusiopathiae strain was determined by inoculating groups of mice subcutaneously with 0.1 mL of a 10-fold dilution of overnight culture. Mice were housed in isolation and observed for 10 days for clinical signs and mortality. The LD 50 was calculated for each strain following the method of Reed and Muench [23] .
Cross-protection studies
A working stock of E. rhusiopathiae standard reference bacterin IRP 529(05) was prepared in sterile 0.85% saline as recommended 
Statistical methods
Live-versus-dead numbers in the cross-protection studies were compared by the Fisher exact test using a two-tailed P-value [25].
Results

Polymerase chain reaction
Polymerase chain reaction (PCR) was performed using primers to detect whole spaA, whole spaB and spaC, and the protective domain of spaA in 83 E. rhusiopathiae strains (Table 1) . Using primers 1/2 and spaA2/F, designed to amplify whole spaA and the protective domain of spaA, respectively, all R.L. Wood strains of serotypes 1a, 1b, 2, 9, 15, 16, 17, and N produced amplification products of appropriate size. Only half of the strains representing serotypes 5, 8, and 12 produced amplicons with both spaA-specific primer sets. There was no gene amplification detected in the R. L. Wood strains of serotypes 4, 6, 11, 19, and 21 with either spaA primer set.
Production of amplification products with both spaA-specific primer sets was variable in fish and cetacean strains of all serotypes. Only strains of serotypes 1b and 2 consistently produced amplification products of expected size with both primers, while only five of 11 fish strains representing the serotypes 5, 6, 8, and 21 produced amplification products. Single strains of serotypes 4 and 21 produced an amplification product with the whole spaA primers, but a product was not produced with the spaA protective domain primers. Three fish strains representing serotype 1a, 12, and 15, respectively, failed to produce an amplicon with either spaA-specific primer set. Only two of six cetacean strains, a serotype 2 Beluga whale strain and a nontypeable dolphin strain, produced amplification products of expected size with both spaA-specific primer sets.
Primers 3/4, designed to amplify whole spaB and spaC, were used to detect those genes from all E. rhusiopathiae fish and cetacean strains, as well as R.L. Wood strains which did not react with the spaA-specific primers. Six of seven fish strains representing serotypes 4, 6, and 21 produced an amplicon of approximately 1880 bp with the primer set. No amplification product was produced from any cetacean strain or strains from the R.L. Wood collection using the spaB/C-specific primer set.
A PCR assay utilizing the E. rhusiopathiae species-specific primers, ERY1F/2R, was used to verify the species of strains nonreactive with any of the spa-specific primers. An amplicon 2210 bp in length was produced from each strain, confirming that these strains were E. rhusiopathiae.
Protective domain sequence comparison
The protective domain of spaA was amplified by PCR from five E. rhusiopathiae strains: swine strain E1-6P (serotype 1a); Beluga whale strain Immiayuk (serotype 2); a nontypeable Pacific whitesided dolphin strain Piquet; and two fish strains, Large Herring 182 (serotype 6) and Large Herring 911 (serotype 21). Alignment of the five deduced amino acid sequences found that the 342 amino acids of the protective region ranged from 98.0% to 99.7% identical to the SpaA protective domain sequence of strain Fujisawa (AB019124); 98.5-99.7% identical to the SpaA protective domain sequence of strain SE-9 (AB024084); 51.7-52.8% identical to the SpaB protective domain sequence of strain Dolphin E-1 (AB238212); and 56.7-57.0% identical to the SpaC protective domain sequence of strain 715 (AB238210).
Expression of spa and reactivity to a SpaA-specific monoclonal antibody
All 83 E. rhusiopathiae strains were examined by SDS-PAGE for their expression of a 64-66 kDa protein and its interaction with the SpaA-specific monoclonal antibody, ERHU-B60-91. In SDS-PAGE analysis, all 83 strains produced a 64-66 kDa protein; however, only those strains which produced an amplicon in PCR with the spaA protective domain primers, spaA2F/R, produced a protein recognizable by ERHU-B60-91 (Table 1) .
Strain lethality testing
Pathogenicity data for each strain are listed in Table 2 . The swine, fish, and cetacean strains appeared nearly equal in their pathogenicity in mice except for strain Large Herring 911 (serotype 21), which at a dose of 3.76 × 10 7 colony forming units (CFU), did not kill mice.
Cross-protection experiment
The experiment was designed to examine whether the standard reference bacterin IRP 529(05), composed of the E. rhusiopathiae serotype 2 SpaA-type strain SE-9, could protect mice equally against challenge with cetacean and fish strains of various Spatypes compared to the serotype 1a SpaA-type swine strain, E1-6P (Fig. 1) .
Within four days after challenge with E1-6P, all nonvaccinated control mice died while all vaccinated mice survived 10 days when the experiment was terminated. The difference between the vaccinated group and the nonvaccinated group was significant (P < 0.0001).
Bacterin IRP 529(05) induced complete protection (100%) against challenge with the SpaA-type dolphin strain Piquet (nontypeable) and the SpaA-type Beluga whale strain Immiayuk (serotype 2). No significant difference was exhibited in the ability of the bacterin to protect mice against Piquet and Immiayuk compared to the E1-6P challenge (P = 1.0000). Of 12 vaccinated mice challenged with the SpaA-type Large Herring 182 (serotype 6), only two sur- vived, indicating a significant difference compared to the results of the E1-6P challenge (P < 0.0001).
Upon challenge with the non-SpaA Beluga whale strain Naluark (nontypeable), seven of 10 vaccinated mice survived, indicating that partial protection was induced compared to the E1-6P challenge (P = 0.2105). The ability of the reference bacterin to protect against challenge with the other non-SpaA-type strains showed significant differences compared to the E1-6P challenge. Four of 10 vaccinated mice challenged with the dolphin strain Quitz (serotype 2, 15) survived (P = 0.0108) while none of the 12 vaccinated mice challenged with the Beluga whale strain Kayavak (serotype 5) survived (P < 0.0001).
Discussion
The Spa proteins of E. rhusiopathiae are cell membrane-bound [12] [13] [14] [16] [17] [18] and recognized as the major protective antigen of the species [15] . This present study investigated a wide range of E. rhusiopathiae strains and found that (i) spa-type is not confined to specific serotype groups, especially in those strains isolated from aquatic animals; (ii) a single E. rhusiopathiae strain may possess more than one spa-type; (iii) the degree of cross-protection elicited by conventional erysipelas bacterins is dependent on the Spa-status of the E. rhusiopathiae challenge strain.
Recently, To and Nagai [17] reported the detection of two additional Erysipelothrix Spa-types, SpaB and SpaC. Based on the Spa-type observed in single reference strains, they reported that serotypes 1a, 1b, 2, 5, 8, 9, 12, 15, 16, 17 and N possess spaA; serotypes 4, 6, 11, 19 and 21 possess spaB; and the unclassified serotype 18 possesses spaC. However, earlier reports by both Wood et al. [7] and Takahashi et al. [6] conflict with this organization in that mice vaccinated with an E. rhusiopathiae serotype 2 (presumably SpaA) strain were variably protected against certain serotypes currently within the SpaA-group, and completely protected against serotypes placed in a heterologous Spa-group. Although, the role of the 64-66 kDa protein was not realized at the time of those studies, and thus not investigated, it is important to consider the role that Spa-type may have had in those evaluations.
In contrast to previous Spa studies [16, 17] , this study investigated several strains per serotype. These strains were analyzed by PCR with primers specific for whole spaA, the protective domain of spaA, and whole spaB and spaC. Fourteen strains of serotypes described as possessing spaA, including, five swine strains representing serotypes 5, 8, and 12; six fish strains representing serotypes 1a, 5, 8, 12 , and 15; and three cetacean strains representing serotypes 8, 5, and 2/15, were non-reactive with either set of spaA-specific primers. After verifying the species identity of these 14 strains, attempts were made to amplify spaB and spaC gene products by PCR, but those assays also yielded negative results. Western blot verified that these 14 strains lacked expression of spaA when the SpaA protective domain-specific monoclonal antibody, ERHU-B60-91, failed to detect the protein. The inability to detect spaA or its expression product in these particular strains is contrary to the observation reported by To and Nagai [17] which suggests that spatype and serotype are related. In this current study, it appears that these 14 strains have either acquired nucleotide variation of spaA or possess a novel spa.
The observation that spa-type and serotype are not associated was further supported when four fish strains representing serotypes 6 and 21 produced amplicons of correct size in PCR assays using both spaA-specific primer sets. Expression of spaA was verified by Western blotting when each of these four strains produced an approximately 65 kDa protein that was detected by ERHU-B60-91. In addition, PCR products resulting from amplification with the spaA protective domain primers were sequenced, translated into amino acid sequences, and aligned with published sequences representing each Spa-type. These sequences showed high identity to the SpaA of both strains Fujisawa and SE-9, demonstrating that E. rhusiopathiae serotypes 6 and 21 (serotypes previously described as possessing spaB) can possess and express spaA.
In this study, primers designed to amplify spaB and spaC [17] were used in PCR with all strains of serotypes 4, 6, 11, 19 , and 21, all fish and cetacean strains, as well as strains non-reactive with spaAspecific primers. Serotype reference strains previously reported as producing a product in PCR with these primers [17] failed to produce an amplification product in this study. Great care was taken to exactly follow the described protocol and several assays were performed to reproduce the published work, but to no avail. However, the spaB/C PCR assay did prove successful with six fish strains representing serotypes 4, 6, and 21, which produced amplicons of expected size. These results indicate the possibility that some genetic variation exists between this laboratory's serotype reference strains and those possessed by To and Nagai [17] , which prevented the spaB/C primers from annealing effectively.
As of yet, E. rhusiopathiae strains have only been described as possessing a single spa-type. In this study, three fish strains representing serotypes 6 and 21 produced amplicons of expected size in each of the three spa-specific PCR assays. Two other fish strains representing serotypes 4 and 21 produced amplicons with the primer sets designed to amplify whole spaA and whole spaB and spaC. Although some cross-reaction is possible due to high sequence similarity of spas in the N-terminal and C-terminal regions, these results imply that a single E. rhusiopathiae strain may possess more than one spa-type. Many more E. rhusiopathiae strains, particularly recent field isolates, must be evaluated to more fully understand the scope and sequence variability of the spa family of genes.
Nearly all commercial erysipelas bacterins are formulated with serotype 2 strains which, in swine, offer cross-protection against the most frequently isolated serotypes, 1a, 1b, and 2 [1] . In this study, the only group of E. rhusiopathiae strains that consistently possessed and expressed a single spa-type were the 33 R.L. Wood strains (mostly clinical swine isolates and vaccine strains) of serotypes 1a, 1b, and 2. These strains all produced a correctly sized amplification product with both spaA-specific primer sets, and expressed a protein recognized by ERHU-B60-91; demonstrating that spaA is highly conserved in serotypes most often implicated in clinical swine erysipelas. The possession and expression of a homologous spa-type likely explain the high rate of cross-protectiveness among these three serotypes.
It has been reported by Lacave et al. [10] that an inactivated E. rhusiopathiae swine vaccine strain of serotype 2 can protect mice against challenge with dolphin strains of serotypes 1a, 2, 5, 15, and 21, but only partial protection was exhibited in the long term. Because the Spa-status of the vaccine strain and the challenge strains were not reported in the study, the effect of Spa-elicited cross-protection is unknown. Due to the immunological significance of the Spa family of proteins [15] [16] [17] [18] 26 ] and the variable cross-protective nature of the three Spa-types currently recognized [17] , it is necessary to evaluate the ability of an erysipelas bacterin to protect against diverse E. rhusiopathiae challenge strains. In this present study, the Spa-type of the E. rhusiopathiae bacterin strain and challenge strains were investigated prior to testing in mice.
Considering To and Nagai's prior cross-protection study [17] , it was not surprising that vaccinated mice were completely protected against challenge strains possessing a single homologous SpaA and variably protected against those strains with a heterologous Spatype. However, it was interesting that protection against Large Herring 182, a serotype 21 fish strain possessing and expressing spaA and possessing at least one other spa-type, was incomplete; only 17% of the vaccinated mice survived challenge against Large Herring 182. This result suggests that antibody to SpaA is not sufficient to protect against an E. rhusiopathiae strain that co-expresses another spa-type. In this study, the spa-type observed in marine animal E. rhusiopathiae isolates was more variable than expected, and may be contributing to the incomplete protection seen in cetaceans vaccinated with commercial swine erysipelas bacterins.
Outbreaks of erysipelas have recently been reported in the Midwestern United States among vaccinated and nonvaccinated swine [2] . Although the outbreaks in these cases were ultimately attributed to inappropriate vaccine management, the variable cross-protective nature of the Spa proteins may reveal the cause of some vaccines' failure to protect. In future erysipelas cases, a comparison of the spa-type(s) of the vaccine and challenge strains should be conducted.
The serotype classification of Erysipelothrix is based on soluble peptidoglycan antigens of the cell surface [1] , and without international guidelines, serotyping results are often inconsistent among laboratories [14] . Molecular-based systems are proving to be a more efficient and reliable method of organizing E. rhusiopathiae strains [5] and assimilation to a new system is anticipated. Because of their significance, a new classification scheme based on spa may be a worthwhile approach.
